KRAS mutational status in japanese patients with colorectal cancer: Results from a nationwide, multicenter, cross-sectional study

Toshiaki Watanabe, Takayuki Yoshino, Hiroyuki Uetake, Kentaro Yamazaki, Megumi Ishiguro, Tatsuo Kurokawa, Nagahiro Saijo, Yasuo Ohashi, Kenichi Sugihara

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: KRAS gene mutations are a useful predictive factor for the efficacy of anti-epidermal growth factor receptor therapeutics. Since there were no large-scale studies among Asian populations, we designed an observational nationwide study in Japan. Methods: Formalin-fixed paraffin-embedded tissue blocks or sections from primary or metastatic lesions were obtained from patients registered between 2009 and 2010 for genomic DNA extraction. KRAS gene was analyzed by direct sequencing or Luminex assay. The primary endpoint was the frequency of KRAS gene mutations and the secondary endpoints were differences in KRAS mutation rates by various stratification factors. Univariate and multivariate analyses were performed to investigate relationships between KRAS mutation rates and patient background factors. Results: We analyzed 5790 eligible samples out of 5887 registered. The overall KRAS mutation rate was 37.6%, with 29.9% in codon 12 and 7.7% in codon 13, and wild type was 62.4%. A significant relationship with the KRAS mutation rate was found for gender, age, the year that the sample was prepared and the site of the primary lesion. Conclusion: The KRAS mutation rate of Japanese colorectal cancer patients was 37.6%. Gender, age, the site of the primary lesion and the year that the sample was prepared were independent risk factors for KRAS mutations.

Original languageEnglish
Pages (from-to)706-712
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume43
Issue number7
DOIs
Publication statusPublished - 2013 Jul

Fingerprint

Mutation Rate
Colorectal Neoplasms
Cross-Sectional Studies
Codon
Mutation
Epidermal Growth Factor Receptor
Gene Frequency
Paraffin
Formaldehyde
Genes
Observational Studies
Japan
Multivariate Analysis
DNA
Population

Keywords

  • Age
  • Gender
  • KRAS
  • Risk factor
  • Site

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

KRAS mutational status in japanese patients with colorectal cancer : Results from a nationwide, multicenter, cross-sectional study. / Watanabe, Toshiaki; Yoshino, Takayuki; Uetake, Hiroyuki; Yamazaki, Kentaro; Ishiguro, Megumi; Kurokawa, Tatsuo; Saijo, Nagahiro; Ohashi, Yasuo; Sugihara, Kenichi.

In: Japanese Journal of Clinical Oncology, Vol. 43, No. 7, 07.2013, p. 706-712.

Research output: Contribution to journalArticle

Watanabe, T, Yoshino, T, Uetake, H, Yamazaki, K, Ishiguro, M, Kurokawa, T, Saijo, N, Ohashi, Y & Sugihara, K 2013, 'KRAS mutational status in japanese patients with colorectal cancer: Results from a nationwide, multicenter, cross-sectional study', Japanese Journal of Clinical Oncology, vol. 43, no. 7, pp. 706-712. https://doi.org/10.1093/jjco/hyt062
Watanabe, Toshiaki ; Yoshino, Takayuki ; Uetake, Hiroyuki ; Yamazaki, Kentaro ; Ishiguro, Megumi ; Kurokawa, Tatsuo ; Saijo, Nagahiro ; Ohashi, Yasuo ; Sugihara, Kenichi. / KRAS mutational status in japanese patients with colorectal cancer : Results from a nationwide, multicenter, cross-sectional study. In: Japanese Journal of Clinical Oncology. 2013 ; Vol. 43, No. 7. pp. 706-712.
@article{8e49bf0cd1bb47fb861f4a6e195e7e09,
title = "KRAS mutational status in japanese patients with colorectal cancer: Results from a nationwide, multicenter, cross-sectional study",
abstract = "Objective: KRAS gene mutations are a useful predictive factor for the efficacy of anti-epidermal growth factor receptor therapeutics. Since there were no large-scale studies among Asian populations, we designed an observational nationwide study in Japan. Methods: Formalin-fixed paraffin-embedded tissue blocks or sections from primary or metastatic lesions were obtained from patients registered between 2009 and 2010 for genomic DNA extraction. KRAS gene was analyzed by direct sequencing or Luminex assay. The primary endpoint was the frequency of KRAS gene mutations and the secondary endpoints were differences in KRAS mutation rates by various stratification factors. Univariate and multivariate analyses were performed to investigate relationships between KRAS mutation rates and patient background factors. Results: We analyzed 5790 eligible samples out of 5887 registered. The overall KRAS mutation rate was 37.6{\%}, with 29.9{\%} in codon 12 and 7.7{\%} in codon 13, and wild type was 62.4{\%}. A significant relationship with the KRAS mutation rate was found for gender, age, the year that the sample was prepared and the site of the primary lesion. Conclusion: The KRAS mutation rate of Japanese colorectal cancer patients was 37.6{\%}. Gender, age, the site of the primary lesion and the year that the sample was prepared were independent risk factors for KRAS mutations.",
keywords = "Age, Gender, KRAS, Risk factor, Site",
author = "Toshiaki Watanabe and Takayuki Yoshino and Hiroyuki Uetake and Kentaro Yamazaki and Megumi Ishiguro and Tatsuo Kurokawa and Nagahiro Saijo and Yasuo Ohashi and Kenichi Sugihara",
year = "2013",
month = "7",
doi = "10.1093/jjco/hyt062",
language = "English",
volume = "43",
pages = "706--712",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - KRAS mutational status in japanese patients with colorectal cancer

T2 - Results from a nationwide, multicenter, cross-sectional study

AU - Watanabe, Toshiaki

AU - Yoshino, Takayuki

AU - Uetake, Hiroyuki

AU - Yamazaki, Kentaro

AU - Ishiguro, Megumi

AU - Kurokawa, Tatsuo

AU - Saijo, Nagahiro

AU - Ohashi, Yasuo

AU - Sugihara, Kenichi

PY - 2013/7

Y1 - 2013/7

N2 - Objective: KRAS gene mutations are a useful predictive factor for the efficacy of anti-epidermal growth factor receptor therapeutics. Since there were no large-scale studies among Asian populations, we designed an observational nationwide study in Japan. Methods: Formalin-fixed paraffin-embedded tissue blocks or sections from primary or metastatic lesions were obtained from patients registered between 2009 and 2010 for genomic DNA extraction. KRAS gene was analyzed by direct sequencing or Luminex assay. The primary endpoint was the frequency of KRAS gene mutations and the secondary endpoints were differences in KRAS mutation rates by various stratification factors. Univariate and multivariate analyses were performed to investigate relationships between KRAS mutation rates and patient background factors. Results: We analyzed 5790 eligible samples out of 5887 registered. The overall KRAS mutation rate was 37.6%, with 29.9% in codon 12 and 7.7% in codon 13, and wild type was 62.4%. A significant relationship with the KRAS mutation rate was found for gender, age, the year that the sample was prepared and the site of the primary lesion. Conclusion: The KRAS mutation rate of Japanese colorectal cancer patients was 37.6%. Gender, age, the site of the primary lesion and the year that the sample was prepared were independent risk factors for KRAS mutations.

AB - Objective: KRAS gene mutations are a useful predictive factor for the efficacy of anti-epidermal growth factor receptor therapeutics. Since there were no large-scale studies among Asian populations, we designed an observational nationwide study in Japan. Methods: Formalin-fixed paraffin-embedded tissue blocks or sections from primary or metastatic lesions were obtained from patients registered between 2009 and 2010 for genomic DNA extraction. KRAS gene was analyzed by direct sequencing or Luminex assay. The primary endpoint was the frequency of KRAS gene mutations and the secondary endpoints were differences in KRAS mutation rates by various stratification factors. Univariate and multivariate analyses were performed to investigate relationships between KRAS mutation rates and patient background factors. Results: We analyzed 5790 eligible samples out of 5887 registered. The overall KRAS mutation rate was 37.6%, with 29.9% in codon 12 and 7.7% in codon 13, and wild type was 62.4%. A significant relationship with the KRAS mutation rate was found for gender, age, the year that the sample was prepared and the site of the primary lesion. Conclusion: The KRAS mutation rate of Japanese colorectal cancer patients was 37.6%. Gender, age, the site of the primary lesion and the year that the sample was prepared were independent risk factors for KRAS mutations.

KW - Age

KW - Gender

KW - KRAS

KW - Risk factor

KW - Site

UR - http://www.scopus.com/inward/record.url?scp=84880174405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880174405&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt062

DO - 10.1093/jjco/hyt062

M3 - Article

C2 - 23657052

AN - SCOPUS:84880174405

VL - 43

SP - 706

EP - 712

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

ER -